AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1 - 2. (presently canceled)

3. (currently amended) A method of treating a patient undergoing treatment with an immunosuppressant comprising a step of administering to the patient a therapeutically effective dose of a protective oligodeoxyribonucleotide ~~for~~ and achieving protection one or both of the patient's epithelial or endothelial cells from one or both of apoptosis or activation induced by the administration of the immunosuppressant.

4. (currently amended) The method according to claim ~~1~~ 3 wherein the immunosuppressant is a nucleoside.

5. (currently amended) The method according to claim ~~1~~ 3 wherein the immunosuppressant is chosen from the group comprising 5-fluorouracil, methotrexate, fludarabine, vincristine, vinblastine, paclitaxel, docetaxel, cyclophosphamide, bischloroethylnitrosurea, melphalan, cisplatin, carboplatin, oxaliplatin, JM-216, Ci-973, doxorubicin, daunorubicin, mitomycin-C, etoposide, camptothecin, cyclosporin, tacrolimus, sirolimus, or combinations thereof.

6. (previously canceled)

7. (currently amended) The method according to claim ~~1~~ 3 wherein the protective oligodeoxyribonucleotide is defibrotide.

8. (currently amended) The method according to claim ~~1~~ 3 wherein the step of administering the protective oligodeoxyribonucleotide occurs as one or more of concurrently with, concomitantly with, simultaneously with, after, or before the administration of the immunosuppressant to the patient.

9. (currently amended) The method according to claim ~~1~~ 3 wherein the step of administering the protective oligodeoxyribonucleotide occurs after that of administering the immunosuppressant to the patient.

10. (previously amended) The method according to claim 9 wherein the time delay between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about one hour to about two weeks.

11. (currently amended) The method according to claim ~~1~~ 3 wherein the step of administering the protective oligodeoxyribonucleotide occurs before that of administering the immunosuppressant to the patient.

12. (previously amended) The method according to claim 11 wherein the time difference between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about one hour to about two weeks.

13. (previously amended) The method according to claim 7 wherein the dose of the defibrotide administered is chosen so as to reach a blood level in the patient from about 100 μg/mL to about 0.1 μg/mL.

14. (previously amended) The method according to claim 13 wherein the dose of defibrotide administered is chosen so as to reach a blood level in the patient of about 10 μg/mL.

15. (previously amended) The method according claim 7 wherein the dose of defibrotide administered is from about 100 mg/kg body weight of the patient to about 0.01 mg/kg body weight.

16. (previously amended) The method according to claim 15 wherein the dose of defibrotide administered is from about 15 mg/kg body weight of the patient to about 1 mg/kg body weight.

17. (previously amended) The method according to claim 3 wherein the activation includes enhanced expression of ICAM-1.

18. (currently amended) The method according to claim ~~1~~ 3 wherein the treatment with an immunosuppressant occurs during stem cell transplantation.

19. (previously amended) The method according to claim 18 wherein the stem cell transplantation is allogeneic stem cell transplantation.

20 - 24. (presently canceled)

25. (previously canceled)

26 - 38. (presently canceled)